Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Thol

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
Leukemia|May 4, 2016
RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic featuresV I Gaidzik, V Teleanu, E Papaemmanuil, et al.
Leukemia|July 5, 2016
Clinical impact of GATA2 mutations in acute myeloid leukemia patients harboring CEBPA mutations: a study of the AML study groupF Theis, A Corbacioglu, V I Gaidzik, et al.
Leukemia|March 21, 2015
Frequency and prognostic impact of casein kinase 1A1 mutations in MDS patients with deletion of chromosome 5qM Heuser, M Meggendorfer, M M A Cruz, et al.
Leukemia|February 8, 2019
Randomized phase-II trial evaluating induction therapy with idarubicin and etoposide plus sequential or concurrent azacitidine and maintenance therapy with azacitidineR F Schlenk, D Weber, W Herr, et al.
Leukemia|February 25, 2017
Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivoA Chaturvedi, L Herbst, S Pusch, et al.
Leukemia|January 19, 2017
Impact of pretreatment characteristics and salvage strategy on outcome in patients with relapsed acute myeloid leukemiaR F Schlenk, P Frech, D Weber, et al.
Annals of Hematology|November 2, 2017
Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO)Gabriele Nagel, D Weber, E Fromm, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Leukemia|May 4, 2016
RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic featuresV I Gaidzik, V Teleanu, E Papaemmanuil, et al.
Leukemia|July 5, 2016
Clinical impact of GATA2 mutations in acute myeloid leukemia patients harboring CEBPA mutations: a study of the AML study groupF Theis, A Corbacioglu, V I Gaidzik, et al.
Leukemia|March 21, 2015
Frequency and prognostic impact of casein kinase 1A1 mutations in MDS patients with deletion of chromosome 5qM Heuser, M Meggendorfer, M M A Cruz, et al.
Leukemia|February 8, 2019
Randomized phase-II trial evaluating induction therapy with idarubicin and etoposide plus sequential or concurrent azacitidine and maintenance therapy with azacitidineR F Schlenk, D Weber, W Herr, et al.
Leukemia|February 25, 2017
Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivoA Chaturvedi, L Herbst, S Pusch, et al.
Leukemia|January 19, 2017
Impact of pretreatment characteristics and salvage strategy on outcome in patients with relapsed acute myeloid leukemiaR F Schlenk, P Frech, D Weber, et al.
Annals of Hematology|November 2, 2017
Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO)Gabriele Nagel, D Weber, E Fromm, et al.
Pageof 3